| Literature DB >> 26268906 |
Jennifer H E Baker1, Kelly C McPhee1, Firas Moosvi1, Katayoun Saatchi2, Urs O Häfeli2, Andrew I Minchinton3, Stefan A Reinsberg1.
Abstract
Macromolecular gadolinium (Gd)-based contrast agents are in development as blood pool markers for MRI. HPG-GdF is a 583 kDa hyperbranched polyglycerol doubly tagged with Gd and Alexa 647 nm dye, making it both MR and histologically visible. In this study we examined the location of HPG-GdF in whole-tumor xenograft sections matched to in vivo DCE-MR images of both HPG-GdF and Gadovist. Despite its large size, we have shown that HPG-GdF extravasates from some tumor vessels and accumulates over time, but does not distribute beyond a few cell diameters from vessels. Fractional plasma volume (fPV) and apparent permeability-surface area product (aPS) parameters were derived from the MR concentration-time curves of HPG-GdF. Non-viable necrotic tumor tissue was excluded from the analysis by applying a novel bolus arrival time (BAT) algorithm to all voxels. aPS derived from HPG-GdF was the only MR parameter to identify a difference in vascular function between HCT116 and HT29 colorectal tumors. This study is the first to relate low and high molecular weight contrast agents with matched whole-tumor histological sections. These detailed comparisons identified tumor regions that appear distinct from each other using the HPG-GdF biomarkers related to perfusion and vessel leakiness, while Gadovist-imaged parameter measures in the same regions were unable to detect variation in vascular function. We have established HPG-GdF as a biocompatible multi-modal high molecular weight contrast agent with application for examining vascular function in both MR and histological modalities.Entities:
Keywords: DCE-MRI; macromolecular; microenvironment; multi-modal imaging; tumor mapping; tumor vessels; vascular function
Mesh:
Substances:
Year: 2015 PMID: 26268906 DOI: 10.1002/cmmi.1661
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.161